Product Images Pregabalin

This is a description of Pregabalin capsules, which contains 25mg of USP. The manufacturer is ScieGen Pharmaceuticals Inc., and it was repackaged by Bryant Ranch Prepack, Inc. The drug should be stored at a temperature of 20°-25°C (68°-77°F). It comes with 90 capsules, and the NDC is 72162-1541-4. The text contains a cautionary statement to keep the drug out of reach of children.*

The data provided is not available for generating a useful description.*

This appears to be a chart showing the percent improvement in pain from baseline for patients taking Pregabalin 160mg for three days. The chart displays percentages ranging from 2% to 100%. There are additional numbers listed, but their significance is unclear without further context.*

This appears to be a chart or table showing percentages and medication dosages for patients with pain. It is not clear how the chart is organized or what the specific data points represent. Therefore, a useful description cannot be generated with the given text.*

This is a medical document that reports on the effects of three treatments on patients. The treatments are Fregabalin 100 mg three times a day, Pregataiin 80 mg three times a day, and Placebo. The document includes a chart that indicates the percentage of patients who improved during the study. There is also a chart that shows the percentage improvement in pain from baseline, with numbers ranging from 0.8 to 100.*

The text provides a graph showing the percent improvement in pain from baseline for Pregabalin at 300mg and 450mg daily doses, as well as a placebo group. The graph plots the percentage of patients improved against the percentage improvement in pain from baseline. There is not enough information to provide a specific description of the study or its findings beyond what is shown in the graph.*

This appears to be a chart or graph displaying the estimated percentage of subjects without LTR for two groups (Progabain and Placebo) over a period of time (0 to 180 days). The x-axis shows the days and the y-axis shows the percentages. It is not clear what the abbreviation "LTR" stands for or what the context of this chart is.*

This is a graph showing the percentage of subjects who improved from baseline to week 16 BOCF (Brought Forward Last Observation Carried Forward) while taking either pregabalin or placebo. The scale ranges from 100 to 280, with significant improvement seen in the pregabalin group compared to placebo.*

This is a calculation to estimate the estimated glomerular filtration rate, or GFR, in adults using their age, weight, and serum creatinine levels. The equation involves subtracting the person's age in years from 140, then multiplying that result by their weight in kilograms. For female patients, the result is then multiplied by 0.85. Finally, the product is multiplied by the person's serum creatinine level in milligrams per deciliter, and divided by 72. This equation is often used to assess kidney function.*